Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Antigenics has entered into definitive agreements to sell in a private placement seven million shares of its common stock at a price of $3 per share, resulting in gross proceeds to the company of $21 million, before deducting placement agent fees and other offering expenses.
Subscribe to our email newsletter
The investors in this private placement will also receive five-year warrants to purchase up to seven million additional shares of common stock at an exercise price of $3.75 per share.
Proceeds from the financing will be used primarily for funding key commercial and regulatory efforts, including the launch of Oncophage (vitespen) in Russia and possible filings in Europe and Canada.
Rodman & Renshaw, a wholly owned subsidiary of Rodman & Renshaw Capital Group, served as the exclusive placement agent for the offering.